MucopolysaccharidosisType I (Hurler Syndrome) R&D Pipeline Analysis Report, H2-2018

August 2018 | 50 pages | ID: M92E170F44CEN
VPAResearch

Abstracts

MucopolysaccharidosisType I (Hurler Syndrome) Drug Development Pipeline Study is the latest publication from VPA Research with comprehensive information of MucopolysaccharidosisType I (Hurler Syndrome) pipeline products.

The MucopolysaccharidosisType I (Hurler Syndrome) pipeline guide presents complete overview of drugs currently being developed for MucopolysaccharidosisType I (Hurler Syndrome). The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the MucopolysaccharidosisType I (Hurler Syndrome) pipeline candidate.

Research and Development progress along with latest news related to each of the MucopolysaccharidosisType I (Hurler Syndrome) pipeline candidates is included.

• Major companies participating in therapeutic development of MucopolysaccharidosisType I (Hurler Syndrome) are included in this pipeline report. Company wise pre clinical and clinical products along with details of drug originator, co developers/ licensors are provided.
• Amid strong interest for cure of MucopolysaccharidosisType I (Hurler Syndrome) from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global MucopolysaccharidosisType I (Hurler Syndrome) clinical and pre clinical products.
• The report assists in identifying potential upcoming companies and drugs in MucopolysaccharidosisType I (Hurler Syndrome) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
• Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

SCOPE OF MUCOPOLYSACCHARIDOSISTYPE I (HURLER SYNDROME) PIPELINE REPORT INCLUDES

• Panorama of MucopolysaccharidosisType I (Hurler Syndrome) pipeline markets including statistics on therapeutic drugs and companies involved
• MucopolysaccharidosisType I (Hurler Syndrome) Pipeline candidates across various development phases including both pre clinical, discovery and clinical stages are covered
• MucopolysaccharidosisType I (Hurler Syndrome) pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
• Overview of companies participating in MucopolysaccharidosisType I (Hurler Syndrome) pipeline with short introduction to their businesses and pipeline projects
• For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co developer and licensee are provided.
• Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with MucopolysaccharidosisType I (Hurler Syndrome) pipeline therapeutics

REASONS TO BUY

• Get clear understanding of the entire MucopolysaccharidosisType I (Hurler Syndrome) pipeline, with details on active projects
• Get in detail information of each product with updated information on each project along with key milestones
• Know the list of companies participating in global MucopolysaccharidosisType I (Hurler Syndrome) pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

Please Note: The report will be delivered in 2 working days after purchase

Contents

I. KEY FINDINGS

1. Companies Investing in MucopolysaccharidosisType I (Hurler Syndrome) Pipeline include
  Number of Companies with MucopolysaccharidosisType I (Hurler Syndrome) projects in pre clinical Development
  Number of Companies with MucopolysaccharidosisType I (Hurler Syndrome) projects in Clinical Development
  MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Companies based in Americas
  MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Companies based in Europe
  MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Companies based in Asia Pacific
  MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Companies based in Rest of the World
2. Pipeline Candidates include
  MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Agents in pre clinical/Discovery stage of Development
  MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Agents in Clinical Development stage
  MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Therapeutic Compounds received special status
  Mechanism of Action of most pipeline Drugs
  Small molecules among the MucopolysaccharidosisType I (Hurler Syndrome) Pipeline agents

II. INSIGHTS INTO MUCOPOLYSACCHARIDOSISTYPE I (HURLER SYNDROME) PIPELINE

1. Disease Overview
  Introduction to MucopolysaccharidosisType I (Hurler Syndrome)
  Symptoms and Causes of MucopolysaccharidosisType I (Hurler Syndrome)
  Treatment or Prevention Options for MucopolysaccharidosisType I (Hurler Syndrome)
  Other Details
2. Phase wise Pipeline Compounds
  MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Pre Clinical/Discovery stage Drugs
  MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Phase 1 stage Drugs
  MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Phase 2 stage Drugs
  MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Phase 3 stage Drugs
  MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Pre Registration stage Drugs
3. Company wise MucopolysaccharidosisType I (Hurler Syndrome) Pipeline Compounds
4. MucopolysaccharidosisType I (Hurler Syndrome) Pipeline by Mechanism of Action

III. MUCOPOLYSACCHARIDOSISTYPE I (HURLER SYNDROME) PIPELINE COMPOUND DETAILS

Drug Details
1. Snapshot
  Name of the Therapeutic Agent
  Originator
  Developing Company
  Co Developer/License Partner
  Orphan Drug/Fast Track/Designation
  Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details

IV. MUCOPOLYSACCHARIDOSISTYPE I (HURLER SYNDROME) PIPELINE COMPANY BRIEFS

V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL MUCOPOLYSACCHARIDOSISTYPE I (HURLER SYNDROME) PIPELINE MARKET

VI. APPENDIX

1. About Us
2. Research Methodology
3. Contact Information

The report will be delivered within 2 working days after procurement. Some of the sections depicted above may be modified in accordance with relevancy and availability